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INTERLEUKIN-6 PLASMA LEVELS AND TUMOR SIZE IN CARDIAC MYXOMA 
Rasjid Soeparwata, MD, ~ Peter Poeml, StudMed, ~Christof Schmid, MD, a Heinz Neuhof, MD, b and Hans H. Scheld, 
MD, a Muenster and Giessen, Germany 
In a certain subset of patients with cardiac myxoma 
noncardiac, onstitutional signs and symptoms that resem- 
ble autoimmune disease are observed, such as hypergam- 
maglobulinemia, fever, autoantibodies, and elevated 
erythrocyte sedimentation rate (ESR) and white blood 
cell count. The conditions that determine whether a 
patient becomes affected by these constitutional signs and 
symptoms are unknown. Interleukin-6 (IL-6), a multifunc- 
tional immunoregulatory c tokine that is involved in 
B-cell differentiation, T-cell activation, acute phase re- 
sponse, and hematopoiesis, has been found in these 
patients, a 
In view of the pleiotropic nature of IL-6 and of cyto- 
kines in general we wanted to know whether there are 
further revealing markers that can be linked to the 
immunologic features of cardiac myxoma. We studied six 
patients with nonfamilial cardiac myxoma (ages 44 to 65 
years; 1 man, 5 women). Diagnosis was established echo- 
cardiographically and confirmed histologically. None of 
the patients had evidence of systemic infection. Endotoxin 
levels were measured to rule out asymptomatic infection. 
All patients gave their informed consent. 
We analyzed preoperative plasma samples for IL-1/3, 
IL-1 receptor antagonist (IL-lra), IL-2, soluble IL-2 re- 
ceptor (slL-2r), IL-6, soluble IL-6 receptor (sIL-6r), IL-8, 
tumor necrosis factor-alpha (TNF-c0, TNF receptor I
(TNF-rI) and I! (TNF-rII), and granulocyte macrophage 
colony-stimulating factor with commercially available n- 
zyme-linked immunosorbent assay kits (Quantikine, R & 
D Systems, Minneapolis, Minn.). Endotoxin levels were 
determined with a modified chromogenic limulus amebo- 
cyte lysate test (Chromogenix, M61ndal, Sweden). The 
normal range of the mediator levels was provided by the 
manufacturer. It is noteworthy that TNF-c~ values may 
give false-negative r sults because of the short half-life of 
this mediator. 
Patient data and results are listed in Table I. Patients 1 
through 4 did not have constitutional symptoms. Patient 1, 
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who had a recurrent but noncomplex myxoma, and patient 
2 were unobtrusive and all studied parameters were within 
normal ranges in these cases. Patient 3 had only a mild 
IL-6 elevation (5.5 pg/ml). In patient 4 there were two 
pathologic findings: an elevation of IL-6 level (9.6 pg/ml) 
and of sIL-6r level (57 ng/ml). 
Patient 5, with increased gamma globulin values, with 
weight loss, anemia, increased ESR, and amaurosis fugax, 
showed an elevation of IL-6 level (12.8 pg/ml), and the 
sIL-6r level (48 ng/ml) was slightly increased. In addition, 
a major increase of IL-1/3 level (10.4 pg/ml) was present, 
and the only finding of increased level of granulocyte 
macrophage colony-stimulating factor (5.6 pg/ml) was 
noted. 
Patient 6 also had constitutional symptoms (elevations 
of ESR, white blood cell count, and C-reactive protein); 
however, the pattern of mediators was different. The 
highest noticed IL-6 level was 15.9 pg/ml and there was an 
increased level of IL-1/3 (1.7 pg/ml) and an outstanding 
high level of IL- lra (2364 pg/ml); furthermore, apart from 
the other cases, there was a mild increase in TNF-c~ (7.9 
pg/ml), TNF-rI (1.5 ng/ml), and TNF-rlI (3.2 ng/ml), q~his 
patient had lentiginosis and pigmented skin lesions and 
was obese, and operation was done under emergency 
conditions because of decompensation f the left side of 
the heart. 
IL-1/3, IL-lra, and IL-6 levels are depicted in Fig. 1. 
Levels of IL-2, sIL-2r, IL-8, and endotoxin were normal 
resp. negative in all cases. 
We calculated an arbitrary index by multiplying the 
three dimensions of the tumor size, and there was a strong 
positive correlation of this index to the circulating IL-6 
amount (r = 0.95,p < 0.005; Fig. 2). Furthermore, a close 
correlation with TNF-rI (r = 0.87, p < 0.05) became 
evident. However, there was no significant correlation 
with sIL-6r (r = 0.38, p = 0.49). The threshold of tumor 
size index for constitutional symptoms was 50 to 150 cm 3, 
inasmuch as all cardiac myxomas less than 50 cm 3 were 
asymptomatic and both myxomas greater than 150 cm 3 
occurred with constitutional symptoms. 
To date, nine cases of cardiac myxoma with elevated 
systemic IL-6 levels have been reported in the literature: 
two of them presented without 2-6 and seven with consti- 
tutional symptoms. 6" 7 In these seven patients and in our 
patients both constitutional symptoms and elevated serum 
IL-6 levels invariably returned to normal after resection of 
the tumor. 2-6 Thus there is convincing evidence that the 
source of IL-6 seems to be aberrant production by the 
tumor, which is substantially supported by the results of 
Seino, Ikeda, and Shimada, ~who found IL-6 messenger 
ribonucleic acid in all three cases they examined. 
Interestingly, all myxoma cell culture supernatants that 
have been reported (12 cases) contained IL-6, indepen- 
dent of whether constitutional symptoms were present or 
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Fig.  1. IL-1/3, I L - l ra ,  and  I L -6  leve ls  in  p lasma of  pat ients  w i thout  (open symbols) and w i th  (solid symbols) 
const i tu t iona l  symptoms.  Upper  border  o f  normal  range  is dep ic ted  by  broken lines. Small black arrows 
i nd icate  respect ive  detect ion  l imi ts .  
Table I. Patient data." cases are listed in order of IL-6 levels 
Case No. 1 [] 2 A 3 © 4 © 5 • 6 • 
Sex, age (yr) M, 44 F, 65 F, 56 F, 60 
Obstruct ion of blood flow - + + - 
Embol ic  phenomena . . . .  
Dyspnea - + + + 
Const i tut ional  symptoms None None None None 
Immunolog ic  mediators  
IL-1/3 . . . .  
I L - l ra  . . . .  
IL-2 . . . .  
sIL-2r - - - 
IL-6 - - (+)  + 
sIL-6r - - - + 
IL-8 - - - 
TNFc~ . . . .  
TNF-r I  . . . .  
TNF-r I I  . . . .  
Endotoxin . . . .  
GM-CSF . . . .  
Site of tumor LA  (relapse) LA  LA  LA  
Size of tumor ( ram)  57×15×15 65X15×15 40×50×20 50×30×35 
F, 61 F, 49 
+ + 
+ 
- + 
ESR elevated; ESR elevated; 
7-globulins elevated; WBC count elevated; 
weight loss; CRP  posit ive 
anemia 
++ + 
- -  ++ 
+ + 
(+)  
- (+) 
-- + 
- -  + 
+ NR 
LA  LA  
60 × 60 X 40 90 × 80 × 25 
M, male; F, female; - ,  normal/negative; +, positive; WBC, white blood cell; CRP, C-reactive protein; GM-CSF, granulocyte macrophage colony-stimulating 
factor; NR, not recorded; LA, left atrium. 
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Fig. 2. Plasma IL-6 level plotted against tumor size index, 
calculated as described in text. Regression line (solid line) 
and 95% confidence interval (broken lines) are shown. 
not.l, 2, 6, 7 Similar results were obtained when messenger 
ribonucleic acid was analyzed. 5 From these observations 
one may conclude that IL-6 production is not an infre- 
quent finding but rather a feature of every cardiac myx- 
oma.  
Why do constitutional symptoms develop in some pa- 
tients and not in others? The physiologic level of IL-6 is 
estimated at 1 to 5 pg/ml. According to our results it might 
well be that constitutional symptoms only manifest after 
IL-6 levels exceed a certain threshold. This 'could be 
settled around 9 pg/ml, inasmuch as our patients were free 
of constitutional symptoms when the IL-6 level was lower 
than 10 pg/ml (Fig. 1) and constitutional symptoms ap- 
peared with levels of 9 pg/ml and higher. 2-7 However, two 
reported cases deviate from this: one with constitutional 
symptoms and an IL-6 level as low as 6 pg/ml 5 and one 
with exceptionally high IL-6 levels (212 pg/ml) but with no 
constitutional symptoms. 6 
Our results show that the amount of circulating IL-6 
directly depends on the size of the tumor, that is, on the 
number of IL-6-producing myxoma cells (Fig. 2). Because 
we found a correlation between tumor size and constitu- 
tional symptoms, a significant concentration response 
relationship of the IL-6 level with the development of 
constitutional symptoms might be proved in larger studies, 
The mechanism by which IL-6 mediates the effects is 
still unclear, but Hirano and associates 1 suggested that 
IL-6 might elicit the formation of autoantibodies, because 
antinuclear autoantibodies have repeatedly been found in 
sera of those patients with high levels of IL-6.1-3' 5 
The interpretation of the overall mediator pattern 
seems to be unwarranted on the narrow basis of these few 
cases. 
In summary, this study demonstrates a significant cor- 
relation between plasma IL-6 level and tumor size in 
patients with cardiac myxoma. Both IL-6 level and tumor 
size could be related to constitutional symptoms. 
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